WOCKPHARMABSEWOCKHARDT LIMITED· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 17 Jul, 2026 · 20:33 IST

Wockhardt AGM notice with capital raise and related party transaction approvals

Related Party TransactionsResults View source PDFExplain this filing

WOCKPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+1.2%Reaction day
₹1902.00
prior close
—
announcement price
After-mkt
timing
Nifty Smallcap 250market+0.1%+1.1% vs market
Pharmaceuticals peers, median of 167sector+0.8%+0.4% vs sector

On the reaction day the stock moved 1.1 pts more than Nifty Smallcap 250 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+1.2+0.1+1.1+0.8+0.4
Next day
-0.6+0.5-1.1+0.8-1.4
2d
-2.2-0.8-1.4-0.5-1.7
3d
-3.0-2.0-1.0-1.6-1.3
4d
-3.0-2.2-0.8-1.5-1.6
5d
-2.0-1.0-1.0-0.6-1.4
1w
+0.7-0.1+0.9-0.9+1.7
15d
+3.2+1.9+1.3+0.6+2.6
1m
-3.8+1.9-5.6-0.7-3.1
2m
+15.0+1.5+13.5+1.8+13.2
3m
-1.1-5.3+4.2-4.6+3.5
UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Wockhardt filed notice for its 27th AGM on Aug 10, 2026 via video conferencing. Items include adoption of FY26 audited results, revision of Executive Chairman Dr Habil Khorakiwala remuneration up to Rs 10 crore per year (ceiling Rs 15 crore) for three years from March 2027, material related party transactions with subsidiaries aggregating up to Rs 2,100 crore, approval to raise additional capital up to Rs 3,000 crore through QIP or other routes, and redeployment of around Rs 162.33 crore unutilised QIP proceeds from the November 2024 placement.

Likely market impact

Shareholders to vote on a large Rs 3,000 crore fundraise, around Rs 2,100 crore subsidiary deals, and higher promoter pay. Possible equity dilution ahead.